



Sociedad Española
de Reumatología -
Colegio Mexicano
de Reumatología

Reumatología Clínica

www.reumatologiaclinica.org



Original Article

Is Palindromic Rheumatism a Pre-rheumatoid Arthritis Condition? Low Incidence of Rheumatoid Arthritis in Palindromic Rheumatism Patients Treated with Tight Control Strategy



Alireza Khabbazi*,¹, Mohammad Mirza-Aghazadeh-Attari, Mohammad Tagi Goli,
Aida Malek Mahdavi, Mehrzad Hajjalilo, Nadereh Rashtchizadeh**,¹

Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

ARTICLE INFO

Article history:

Received 26 August 2018

Accepted 10 January 2019

Keywords:

Palindromic rheumatism
Rheumatoid arthritis
Disease-modifying anti-rheumatic drugs
Remission

ABSTRACT

Objectives: Palindromic rheumatism (PR) is characterized by repetitive, afebrile episodes of acute arthritis and peri-arthritis. The aim of this study was considering the long-term outcomes of patients with PR who were treated with tight control strategy using Disease-modifying anti-rheumatic drugs (DMARDs).

Methods: We reviewed the charts of 106 patients diagnosed with PR who were referred to the Connective Tissue Diseases Research Center (CTDRC). We recruited all the patients diagnosed with PR according to the criteria of Hannonen. They visited the CTDRC clinic regularly and were treated with hydroxychloroquine and low dose prednisolone because of active episodes of PR. In cases that the attacks did not come under control in 3–6 months, methotrexate was added or replaced and the dose was increased up to 25 mg/week. In resistant cases, sulfasalazine was added, followed by the addition of leflunomide and then azathioprine. Disease outcome was evaluated by getting complete or partial remission and prevention of disease evolution to rheumatoid arthritis (RA) or other inflammatory connective tissue diseases.

Results: This study included 92 patients with PR who were treated with DMARDs. Attacks were controlled completely or partially in 76 (82.6%) patients. Medications free remission was obtained in 16.3% of the patients. RA developed in 8.7% of the patients. By multivariate logistic regression analysis, age ≤ 40 at disease presentation, non-adherence to therapy and PIP joints involvement were the only factors which independently predicted the risk of treatment failure.

Conclusions: Tight control strategy by using DMARDs may control PR and prevent disease progression to RA.

© 2019 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

¿Es el reumatismo palindrómico una condición de artritis pre-reumatoide? Baja incidencia de artritis reumatoide en pacientes con reumatismo palindrómico tratados con estrategia de control estricta

RESUMEN

Palabras clave:

Reumatismo palindrómico
Artritis reumatoide
Fármacos antirreumáticos modificadores
de la enfermedad
Remisión

Objetivos: El reumatismo palindrómico (PR) se caracteriza por episodios repetitivos y afebriles de artritis aguda y periartrosis. El objetivo de este estudio fue considerar los resultados a largo plazo de los pacientes con PR que fueron tratados con una estrategia de control estricta utilizando fármacos antirreumáticos modificadores de la enfermedad (DMARD).

Métodos: Revisamos los cuadros de 106 pacientes diagnosticados con PR que fueron remitidos al Centro de Investigación de Enfermedades de Tejido Conectivo (CTDRC). Reclutamos a todos los pacientes diagnosticados con PR según los criterios de Hannonen. Visitaron la clínica de CTDRC regularmente y

* Corresponding author.

** Co-corresponding author.

E-mail addresses: dr.khabbazi@yahoo.com, khabbazia@tbzmed.ac.ir (A. Khabbazi), rashtchizadeh@rocketmail.com (N. Rashtchizadeh).

¹ These authors contributed equally to this work and should be considered as Co-corresponding authors.

fueron tratados con hidroxyclorequina y prednisolona a dosis bajas debido a episodios activos de PR. En los casos en que los ataques no se controlaron en 3 a 6 meses, se agregó o reemplazó metotrexato y la dosis se aumentó hasta 25 mg/semana. En casos resistentes, se añadió sulfasalazina, seguido de la adición de leflunomida y luego azatioprina. El resultado de la enfermedad se evaluó obteniendo la remisión completa o parcial y la prevención de la evolución de la enfermedad a la artritis reumatoide (AR) u otras enfermedades inflamatorias del tejido conectivo.

Resultados: Este estudio incluyó 92 pacientes con PR que fueron tratados con DMARD. Los ataques fueron controlados total o parcialmente en 76 (82,6%) pacientes. La remisión libre de medicamentos se obtuvo en el 16,3% de los pacientes. La AR se desarrolló en el 8,7% de los pacientes. Mediante el análisis de regresión logística multivariante, la edad ≤ 40 en la presentación de la enfermedad, la no adhesión al tratamiento y la afectación de las articulaciones PIP fueron los únicos factores que predijeron de forma independiente el riesgo de fracaso del tratamiento.

Conclusiones: Una estrategia de control estricta mediante el uso de DMARD puede controlar la RP y prevenir la progresión de la enfermedad a AR.

© 2019 Elsevier España, S.L.U.

y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

Introduction

Palindromic rheumatism (PR) is a clinical syndrome characterized by repetitive, afebrile episodes of acute arthritis and peri-arthritis, lasting from a few hours to several days with variable frequency and producing no permanent tissue damage. Arthritis attacks usually are monoarticular and may appear in any joint, but proximal interphalangeal (PIP) joints, metacarpophalangeal (MCP) joints, wrists, and knees are most commonly affected.^{1,2} PR, in addition to reducing the quality of life, may also be transformed into chronic inflammatory connective tissue diseases. Several case series with long-term follow-up showed that 28–67% of PR cases evolve into rheumatoid arthritis (RA) and other inflammatory connective tissue diseases.^{3–11}

Despite the relatively high frequency of this disease and significant risk of developing RA, no controlled clinical trials have been performed and no consensus exists on the best therapeutic strategy for PR.^{12,13} Patients may be treated with non-steroidal anti-inflammatory drugs (NSAIDs) or steroids during attacks.^{12,13} Disease-modifying anti-rheumatic drugs (DMARDs) like hydroxychloroquine (HCQ), D-penicillamine, gold salts and sulfasalazine (SSZ) have been used for prophylaxis of attacks and prevention of disease evolution to RA but have not been evaluated systematically.¹²

The aim of this study was considering the long-term outcomes of patients with PR who were treated with tight control strategy using DMARDs.

Materials and methods

We reviewed the charts of 106 patients who were referred to the Connective Tissue Diseases Research Center (CTDRC) with diagnosis of PR from October 2005 to November 2017. We recruited all the patients diagnosed with PR according to the criteria of Hannonen (Box 1)¹⁴ and were treated with DMARDs because of active episodes of PR. The disease activity was evaluated by phone call in patients who had not been visited in the last 6 months. In cases

where the phone call was not possible, the patient was excluded from the study. Written informed consent was obtained from all the patients and the study protocol was approved by the Ethics Committee of Tabriz University of Medical Sciences. The study protocol was in compliance with the Helsinki declaration.

Data relating to the demographic characteristics, clinical manifestations, laboratory findings, therapies and adherence to therapy were extracted from medical notes. Adherence to treatment was evaluated by the 5-item version of the Compliance Questionnaire for Rheumatology (CQR5) questionnaire.¹⁵ Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) were measured in all patients at the first visit. Disease outcome was evaluated by getting complete or partial remission and prevention of disease evolution to RA or other inflammatory connective tissue diseases. Complete remission was defined as complete stopping of the attacks for 12 weeks. Partial remission was defined as at least 50% reduction in the frequency of attacks for 12 weeks. For the purpose of this analysis, treatment failure was defined as decreasing less than 50% in the frequency of attacks (persistent PR) or conversion of PR to RA. Based on the CTDR protocol treatment with DMARDs was performed in all the patients with attacks that impaired their quality of life. The treatment was started with the hydroxychloroquine (HCQ) 5 mg/kg/d and low dose prednisolone (5–10 mg/d). If remission was attained, the dose of prednisolone was tapered 1.25 mg/d every 8–16 weeks and then discontinued. In cases that the attacks did not come under control in 3–6 months or that the patient did not tolerate the HCQ, methotrexate (MTX) 10 mg/week was added or replaced and the dose was increased up to 25 mg/week. In resistant cases, sulfasalazine (SSZ) 1500–2000 mg/d was added, followed by the addition of leflunomide 20 mg/d and then azathioprine 2–2.5 mg/kg/d. All the patients were visited and their responses to the treatment were evaluated every 8–16 weeks.

Statistical analysis was performed using SPSS version 16.0 software (SPSS Inc., Chicago, IL). Distribution of the data was assessed using Kolmogorov–Smirnov test. *T*-test was used to compare the quantitative data, and chi squared test was used to compare the qualitative data. *P*-value less than 0.05 was considered significant. We carried out multivariate analyses with a logistic regression model with disease remission as the main outcome variable to calculate odds ratios with 95% confidence intervals (OR, 95% CI). Models were adjusted for age, gender, body mass index (BMI), smoking status, disease duration before treatment, frequency of attacks, duration of attacks, number of involved joints in each attack, involved joints, seropositivity for RF or anti-CCP and adherence to therapy. *P*-value less than 0.05 was considered significant.

Box 1: Hannonen diagnostic criteria for palindromic rheumatism.

1	Recurrent attacks of sudden-onset mono or polyarthritis or of periarticular tissue inflammation, lasting from a few hours to one week
2	Observation of at least one attack by a physician
3	Three or more different joints involved in different attacks
4	Exclusion of other forms of arthritides

Table 1
Demographic, clinical and paraclinical characteristics of included patients (n=92).

Age at the time of diagnosis	42.3 ± 13.2 (min 18, max 76)
Disease duration before diagnosis (months)	24.8 ± 6.4 (min 6.5, max 240)
Female/male	53/39 (1.4)
Frequency of attacks (weeks)	3.2 ± 1.9 (min 0.2, max 18)
Duration of attacks (days)	2.6 ± 1.5 (min 0.2, max 7)
Number of involved joints in each attack	1.2 ± 0.5 (min 1, max 4)
Involved structures	
Knees (%)	63 (68.5)
MCP joints (%)	51 (55.4)
Shoulders (%)	52 (56.5)
Wrists (%)	49 (53.3)
Hand PIP joints (%)	45 (48.9)
Ankles (%)	33 (35.9)
Elbows (%)	21 (22.8)
MTP joints (%)	12 (13)
Hips (%)	8 (8.7)
Foot PIP joints	6 (6.5)
Periarticular structures (%)	10 (10.9)
Positive RF (%)	39 (42.4)
Positive anti-CCP (%)	58 (63)
Serum 25(OH)D	28.6 ± 8.2

MCP, metacarpophalangeal; PIP, proximal interphalangeal; MTP, metatarsophalangeal; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; 25(OH)D, 25 hydroxy vitamin D.

Results

One hundred and six patients diagnosed with PR were considered for eligibility, 14 patients were excluded (6 patients were not treated with DMARDs and 8 patients were lost the follow up) and finally 92 patients were included in this study. Demographic, clinical and laboratory characteristics of the participants at the baseline are presented in [Table 1](#). Attacks were controlled completely or partially in 76 (82.6%) patients ([Table 2](#)). Prednisolone dose was decreased from 7.4 to 3.1 mg/d. Medications' free remission was obtained in 16.3% of the patients. RA was developed in 8.7% of the cases ([Table 2](#)). [Table 3](#) presents clinical and paraclinical characteristics of PR patients with and without response to treatment. All of the cases of RA were developed within 3 years after the diagnosis of PR ([Fig. 1](#)). By multivariate logistic regression analysis, age ≤40 at disease presentation, non-adherence to therapy and hand PIP joints involvement were the only factors which independently predicted the risk of treatment failure. The relative risk (RR) of treatment failure were 11.2 ($P=0.023$, 95% CI = 2.1–10.8), 14.6 ($P=0.003$, 95% CI = 2.1–25.4) and 8.6 ($P=0.044$, 95% CI = 1.5–34.2) for age ≤40, non-adherence to therapy and PIP joints involvement, respectively.

Table 3
Clinical and paraclinical characteristics of palindromic rheumatism patients with and without response to treatment.

Parameters	Response to treatment (N=76)	No response treatment (N=16)	P-value
Age ≤40	26 (34.2)	9 (56.3)	0.05
Female/male	44/32 (1.4)	9/7 (1.3)	NS
BMI	26.6 ± 4.9	25.3 ± 3.1	NS
Smokers	16 (21.1)	4 (25)	NS
Disease duration before treatment (months)	22.1 ± 9.3	34.1 ± 8.8	NS
Frequency of attacks (weeks)	3.1 ± 1.9	4.3 ± 2.1	NS
Duration of attacks (days)	2.4 ± 1.8	2.8 ± 1.3	NS
Number of joints in each attack	1.1 ± 0.3	1.3 ± 0.1	0.031
Hand PIP joints involvement (%)	33 (43.3)	12 (75)	0.035
MCP joints involvement (%)	41 (53.9)	10 (62.5)	NS
Wrist involvement (%)	39 (48.5)	8 (50)	NS
Shoulder involvement (%)	42 (55.3)	9 (56.3)	NS
Elbow involvement (%)	18 (23.7)	3 (18.8)	NS
Knee involvement (%)	55 (72.4)	8 (50)	0.05
Ankle involvement (%)	27 (35.7)	6 (37.5)	NS
Positive RF	32 (42.1)	7 (43.8)	NS
Positive anti-CCP	48 (63.2)	10 (62.5)	NS
Adherents to therapy	60 (78.9)	5 (31.23)	0.001

NS, non-significant; BMI, body mass index; PIP, proximal interphalangeal; MCP, metacarpophalangeal; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide.

Table 2
Patients medications and outcomes of treatment (n=92).

Medications	
Prednisolone (%)	88 (95.7)
Hydroxychloroquine (%)	86 (93.5)
Methotrexate (%)	38 (41.3)
Sulfasalazine (%)	8 (8.7)
Azathioprine (%)	2 (2.2)
Leflunomide (%)	1 (1.1)
Duration of follow-up (months)	33.3 ± 22.5 (min 3, max 108)
Disease activity status	
Complete remission (%)	64 (69.6)
Partial remission (%)	12 (13)
Active disease (%)	8 (8.7)
Conversion to RA (%)	8 (8.7)
Flare up of disease during treatment	
Time to complete or partial remission (weeks)	35 (38)
Initial prednisolone dose	58.1 ± 32.1 (min 6, max 420)
Final prednisolone dose	7.4 ± 2.5
Prednisolone discontinuation (%)	3.1 ± 2.8
30 (32.6)	
DMARDs therapy status	
Continuation of initial DMARD (%)	48 (52.2)
Changing of initial DMARD because of ineffectivity or intolerance (%)	6 (6.5)
Combination therapy with DMARDs (%)	23 (25)
Discontinuation of DMARDs because of remission (%)	15 (16.3)
Duration of remission (months)	22.9 ± 17.6 (min 3, max 93)

DMARDs, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis.

Discussion

The present study showed that tight control strategy by DMARDs controlled PR attacks successfully and only 8.7% and 8.7% of the patients had persistent PR or developed RA after 33.3 months, respectively. However, therapy with the initial DMARD was continued in 52.2% of the cases and in 23% of the cases combination therapy with DMARDs was performed. Steroid free and medication free remission happened in 32.6% and 16.6% of the PR patients, respectively. Patients with age ≤40 at disease presentation, PIP joints involvement and non-adherent patients had the worst outcome. There was no significant relationship between sex, BMI, smoking status, RF or anti-CCP status and response to the treatment.

Some uncontrolled studies reported the efficacy of DMARDs in controlling PR attacks and preventing disease evolution to RA. In a report on 5 patients with PR, using D-penicillamine completely




Fig. 1. Kaplan-Meier estimates of the cumulative probability of remission.

controlled the attacks in 4 patients.¹⁶ In a report by Hanonen et al., gold, HCQ and SSZ were effective in controlling PR in 9 out of 16 patients, 8 out of 17 patients and 3 out of 8 patients, respectively¹⁴. In another report by Hanonen et al., gold was effective in the treatment of 26 out of 50 patients with PR.¹⁷ However, it was stopped because of side effects in 14 patients.¹⁷ Golding in a study on 14 patients with PR reported that treatment with SSZ 2 g/d successfully controlled attacks in 8 patients.¹⁸ Youssef et al., in a study on 71 PR patients in which 51 patients were treated with anti-malarials, reported that 77.5% and 63% of the patients experienced reduction in frequency and duration of attacks, respectively.¹⁹ Sixteen out of 71 patients developed RA.¹⁹ Gonzalez-Lopez et al., in a retrospective study on 113 PR patients, 55% of which were treated with HCQ, reported that 32% of the cases in the HCQ group and 39% of the patients who did not receive therapy developed RA or other inflammatory connective tissue diseases.⁷ Treatment with HCQ significantly reduced the risk of chronic inflammatory connective tissue diseases development (hazard ratio = 0.24).⁷ Shinjo et al. reported a case of PR associated with hypertrophic osteoarthropathy who had a good response to MTX.²⁰ To the best of our knowledge, no studies published on the use of leflunomide, cyclosporine, mycophenolate mofetil, cyclophosphamide or biologics in the treatment of PR.

The results of our study about predictive factors of prognosis in PR were different from the previous studies. Contrary to our study, in Gonzalez-Lopez study on 127 PR patients with mean follow-up of 40 months, 34% of the patients subsequently developed a connective tissue disease.⁷ The hazard ratio for the development of a chronic condition in patients with a positive RF was 2.9, it was 2.4 for PIP joints involvement, 2.5 for wrist involvement, 2.2 for female sex and 1.03 for age at onset (per year).⁷ Koskinen et al. studied the progression of PR to RA in 60 patients with PR.¹⁰ Fifty-eight patients were treated with DMARDs.¹⁰ In a follow up of 20 years, two-thirds of the patients developed RA. Positive RF was significantly more common in those who developed RA.¹⁰ Sanmartí et al. conducted a similar study on 71 PR patients.²¹ In sixteen of the cases (22.5%) PR progressed to RA. Interestingly, no significant association was found between sex, anti-CCP positivity and treatment with HCQ and evolution of disease to RA.²¹ However, 87.5% of the patients who developed RA were RF positive; while this figure for patients with persistent PR was 48.9%.²¹ The difference was significant.²¹ Russel et al., in their study on 61 PR patients with a mean follow-up of 5.4 years, showed that in 29 cases the disease had progressed to RA.⁹ The positive predictive value of RF and anti-CCP to predict disease progression to RA were 60% and 71%, respectively.⁹ In Tamai et al. study on 28 PR patients with mean follow-up of 38

months, 11 patients developed RA.²² PIP joint involvement and positive anti-CC were the only predictors. In Chen et al. study on 84 patients with PR, having the sonographic findings of synovitis and a positive anti-CCP were significant predictors for progression of PR to RA.²³ Compared to previous studies, a low probability of RA development in our study may be related to using a low dose of prednisolone and sequential DMARDs therapy in all the patients with active PR in our center and also a relatively lower follow-up duration. The different disease duration before diagnosis, different treatment strategies and different follow-up duration may explain the difference in predictive factors of disease prognosis in our study and previous studies.

The main limitations of our study were the retrospective design of the study, a relatively short follow-up duration and the scarcity of patients who were resistant to treatment or had developed RA. The strength of our study was the uniformity of the treatment strategy in all the patients.

Conclusion

Tight control strategy by using DMARDs may control PR and prevent disease progression to RA.

Funding

This research was funded by the Connective Tissue Diseases Research Center of Tabriz University of Medical Sciences.

Conflict of interest

We declare that we have no potential conflict of interest.

Acknowledgements

We are grateful to Dr. L. Khabbazi for editing this manuscript.

References

- Sanmarti R, Canete JD, Salvador G. Palindromic rheumatism and other relapsing arthritis. *Best Pract Res Clin Rheumatol.* 2004;18:647–61.
- Khabbazi A, Hajjaliloo M, Kolahi S, Soroosh M, Esalatmanesh K, Sharif S. A multicenter study of clinical and laboratory findings of palindromic rheumatism in Iran. *Int J Rheum Dis.* 2012;15:427–30.
- Mattingly S. Palindromic rheumatism. *Ann Rheum Dis.* 1966;25:307–17.
- Williams MH, Sheldon PJ, Torrigiani G, Eisen V, Mattingly S. Palindromic rheumatism. Clinical and immunological studies. *Ann Rheum Dis.* 1971;30:375–80.
- Wajed MA, Brown DL, Currey HL. Palindromic rheumatism. Clinical and serum complement study. *Ann Rheum Dis.* 1977;36:56–61.

6. Bregeon C, Dajon JL, Renier G, Jegoude-Mauco F, Galland F, Fallah N, et al. [Palindromic rheumatism. Immunologic survey and study of development in 43 cases]. *Rev Rhum Mal Osteoartic.* 1986;53:441–9.
7. Gonzalez-Lopez L, Gamez-Nava JI, Jhangri GS, Ramos-Remus C, Russell AS, Suarez-Almazor ME. Prognostic factors for the development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism. *J Rheumatol.* 1999;26:540–5.
8. Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, Russell AS, Suarez-Almazor ME. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. *J Rheumatol.* 2000;27:41–69.
9. Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. *J Rheumatol.* 2006;33:1240–2.
10. Koskinen E, Hannonen P, Sokka T. Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967–84. *J Rheumatol.* 2009;36:1873–5.
11. Butbul-Aviel Y, Uziel Y, Hezkelo N, Brik R, Amariyo G. Is palindromic rheumatism amongst children a benign disease? *Pediatr Rheumatol Online J.* 2018;13:12.
12. Cabrera-Villalba S, Sanmartí R. Palindromic rheumatism: a reappraisal. *Int J Clin Rheumatol.* 2013;8:569–77.
13. Mankia K, Emery P. What can palindromic rheumatism tell us? *Best Pract Res Clin Rheumatol.* 2017;31:90–8.
14. Hannonen P, Möttönen T, Oka M. Palindromic Rheumatism A. Clinical survey of sixty patients. *Scand J Rheumatol.* 1987;16:413–20.
15. Hughes LD, Done J, Young A. A 5 item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs. *BMC Musculoskelet Disord.* 2013;14:286.
16. Huskisson E. Treatment of palindromic rheumatism with D-penicillamine. *Br Med J.* 1976;2:979.
17. Hanonen P, Mottonen T, Oka M. Treatment of palindromic rheumatism with chloroquine. *Br Med J (Clin Res Ed).* 1987;294:1289.
18. Golding D. Sulphasalazine for palindromic rheumatism. *Rheumatology.* 1988;27:79.
19. Youssef W, Yan A, Russell AS. Palindromic rheumatism: a response to chloroquine. *J Rheumatol.* 1991;18:35–7.
20. Shinjo SK, Levy-Neto M, Borba EF. Palindromic rheumatism associated with primary hypertrophic osteoarthropathy. *Clinics.* 2006;61:581–3.
21. Sanmartí R, Cabrera-Villalba S, Gómez-Puerta JA, Ruiz-Esquide V, Hernández MV, Salvador G, et al. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A long term follow up study. *J Rheumatol.* 2012;39:1929–33.
22. Tamai M, Kawakami A, Iwamoto N, Arima K, Aoyagi K, Eguchi K. Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism. *Scand J Rheumatol.* 2010;39:287–9.
23. Chen HH, Chen DY, Hsieh TY, Hung GD, Lan HH, Hsieh CW, et al. Predicting the progression of palindromic rheumatism to rheumatoid arthritis: the role of ultrasonography and anti-cyclic citrullinated peptide antibodies. *J Med Ultrasound.* 2010;18:17–26.